Carcinoma, non-small-cell lung Trials in Nanning, China
Conditions / Carcinoma, non-small-cell lung / Nanning, China
Carcinoma, non-small-cell lung is a medical condition with active clinical research programs worldwide.
16 total trials for this combination
Showing top 10 of 16 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06012435 | A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06875310 | A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | RECRUITING | — |
| NCT06140836 | A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06890598 | Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer | RECRUITING | PHASE3 |
| NCT06855771 | A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9) | RECRUITING | — |
| NCT06868277 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer | RECRUITING | — |
| NCT03745222 | A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer | TERMINATED | PHASE3 |
| NCT03706690 | A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06758401 | This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. | RECRUITING | PHASE3 |
| NCT05609968 | Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) | ACTIVE_NOT_RECRUITING | PHASE3 |